Meet the editors

Mark Feitelson received his Ph.D. in Microbiology and Immunology from UCLA in 1979. He began his work on the pathogenesis of chronic hepatitis B at Stanford University and was then recruited to the Fox Chase Cancer Center by Nobel laureate Dr. Baruch Blumberg. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became a Professor of Pathology and Cell Biology and director of the Molecular Diagnostics

Lab in Microbiology. In 2007, Dr. Feitelson was appointed Professor of Biology at Temple University. He is also the CSO of SFA Therapeutics. His work has been supported by NIH, industry and foundations, and he has mentored over 130 students. He has more than 150 publications, 180 abstracts and 11 patents.

Alla Arzumanyan received her Ph.D. in Biotechnology from Yerevan State University, Armenia in 2003. She pursued postdoctoral training at Temple University and Thomas Jefferson University in Philadelphia, USA. In 2008 she joined Dr. Feitelson's group and is currently a Research Associate Professor. She has worked on the pathogenesis of hepatitis B and has developed an artificial immune system to diagnose serious human patho-

gens. She is Chief Development Officer for SFA Therapeutics and has developed a novel microbiome-based treatment for plaque psoriasis. She has co-authored 17 original papers and three book chapters, and has presented 17 posters/invited talks.
